Finance

Lists
Why is IPHA down 8.27%?
Dive Deeper
IPHA:NASDAQ
Innate Pharma SA
$1.49
-8.27%
(-0.13) 1D
Oct 12, 2:18:50 PM GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for IPHA...
Open
$1.48
High
$1.53
Low
$1.46
Mkt. cap
148.45M
Avg. vol.
50.11K
Volume
28.35K
52-wk high
$2.71
52-wk low
$1.17
EPS
-$0.57
Beta
0.72
Shares outstanding
111.72M
No. of employees
120
Open
$1.48
High
$1.53
Low
$1.46
Mkt. cap
148.45M
Avg. vol.
50.11K
Volume
28.35K
52-wk high
$2.71
52-wk low
$1.17
EPS
-$0.57
Beta
0.72
Shares outstanding
111.72M
No. of employees
120
News stories
From web sources and news partners
About Innate Pharma SA
CEO-
Employees120
Founded1999
Headquarters-
SectorBiotechnology
Websiteinnate-pharma.com
Analyst ratings
Based on 3 analysts giving stock ratings to IPHA in the past 3 months
Strong buy
Buy
3
Hold
0
Sell
0
12-month forecast
Based on 3 Wall Street analysts offering 12 month price targets for IPHA in the last 3 months.
Highest
Current $1.49
$9.00 (+505.61%)
Average
$6.67 (+348.83%)
Lowest
$4.00 (+169.16%)
Analyst
Recommendation
Action
Price target
Projected
Date
Swayampakula Ramakanth
H.C. Wainwright
Buy
Reiterated
$7.00
+371%
10/01/2026
Jeet Mukherjee
BTIG
Buy
Maintained
$9.00
+505.6%
09/17/2026
Daina Graybosch
Leerink Partners
Buy
Upgraded
$4.00
+169.2%
08/11/2026
Christopher Liu
Lucid Capital
Buy
Initiated
$8.00
+438.3%
10/23/2025
Last report
Sep 17, 2026
Fiscal period
Q2 2026
- / -
Revenue / Est. (EUR)
2.83M / 7.89M
Fiscal Q2 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in EUR
Loading Previous Earnings...
Revenue
Net income
All values in EUR
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Revenue
2.07M
2.07M
2.83M
2.83M
Cost of goods sold
11.55M
11.55M
8.44M
8.44M
Cost of revenue
11.55M
11.55M
8.44M
8.44M
Research and development expenses
-
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
4.81M
4.81M
3.90M
3.90M
Operating expense
4.81M
4.81M
3.90M
3.90M
Total operating expenses
16.36M
16.36M
12.34M
12.34M
Operating income
-14.29M
-14.29M
-9.51M
-9.51M
Other non operating income
144.00K
144.00K
44.00K
44.00K
EBT including unusual items
-13.92M
-13.92M
-9.81M
-9.81M
EBT excluding unusual items
-13.92M
-13.92M
-9.81M
-9.81M
Income tax expense
-
-
-
-
Effective tax rate
-
-
-
-
Other operating expenses
-
-
-
-
Net income
-13.92M
-13.92M
-9.81M
-9.81M
Net profit margin
-671.48%
-671.48%
-346.51%
-346.51%
Earnings per share
-
-
-
-
Interest and investment income
262.50K
262.50K
139.50K
139.50K
Interest expense
-105.50K
-105.50K
-85.00K
-85.00K
Net interest expenses
157.00K
157.00K
54.50K
54.50K
Depreciation and amortization charges
-
-
-
-
EBITDA
-14.12M
-14.12M
-9.36M
-9.36M
Gain or loss from assets sale
1.50K
1.50K
96.50K
96.50K
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google apps